Implantable LVAD (Left Ventricular Assist Device) in addition to guideline directed medical therapy (GDMT) in end stage heart failure

Left ventricular assist device (LVAD) is considered an alternative to transplantationin end stage acute or chronic left ventricular congestive heart failure (HF). Use of LVAD improves the allocation of transplants alleviating the shortage of donors. The target population of the technology is represented by patients with end stage heart failure.

Objectives: To assess the effect of using a LVAD in addition to guideline directed medical therapy (GDMT) (including Cardiac Resynchronization Therapy Defibrillator CRT-P, implantable cardioverter-defibrillator ICD and Cardiac Resynchronization Therapy Defibrillator CRT-D) in adult patients with end stage heart failure who are not eligible or immediately eligible for cardiac transplant in stage D of the ABCD classification of the American College of Cardiology (ACC)/American Heart Association (AHA), and class III–IV of the New York Heart Association (NYHA) functional classification.